We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Solentim To Supply Cell Line Development Solutions for New R&D Center in San Francisco

Credit: Solentim

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Solentim To Supply Cell Line Development Solutions for New R&D Center in San Francisco"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Solentim is pleased to announce the adoption of its VIPS™ single cell seeding platform and Cell Metric® CLD into Samsung Biologics’ new research and development facility in San Francisco, CA. These instruments are designed for single cell cloning and assurance of monoclonality to increase the speed and efficiency of Master Cell Bank development.

Samsung’s new R&D facility in San Francisco will offer rapid, high-quality development services, including cell line development, to its global customers. Solentim’s VIPS and Cell Metric CLD instruments will be used in conjunction with Samsung Biologics’ recently launched proprietary cell line platform, S-CHOice™, announced last month.

Dr Mark Truesdale, CEO of Solentim, said, “We’re pleased to extend our long-standing partnership with Samsung Biologics, which has previously purchased and enjoyed success with our equipment in its headquarter operations.”